Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Use of shikonin as antifungal medicine synergist

An antifungal drug, shikonin technology, applied in the field of medicine to reduce toxic side effects and treat fungal infections

Inactive Publication Date: 2012-08-29
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But so far there is no report that shikonin can be used as a synergist of antifungal drugs such as azoles or polyenes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of shikonin as antifungal medicine synergist
  • Use of shikonin as antifungal medicine synergist
  • Use of shikonin as antifungal medicine synergist

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0010] Example 1: Effects of combined use of shikonin and fluconazole on different clinical fungal strains.

[0011] Materials and methods

[0012] 1. Test drug:

[0013] Shikonin: National Institute for the Control of Pharmaceutical and Biological Products (the same below).

[0014] Fluconazole: Pfizer Pharmaceutical Co., Ltd. (the same below).

[0015] Dimethyl sulfoxide: China Pharmaceutical (Group) Shanghai Chemical Reagent Company.

[0016] The concentration of shikonin was 8 mg / ml, the concentration of fluconazole was 2 mg / ml, and the tested drugs were stored at -20°C. Before the experiment, the drug stock solution was taken out and placed in a 35°C incubator to melt, fully mixed, and the pharmacodynamic test was carried out respectively.

[0017] 2. Strains:

[0018] The clinical strains of Candida albicans, Candida krusei and Microsporum lanoides were provided by the fungal laboratory of Shanghai Changhai Hospital, and were identified by morphology and biochemistr...

Embodiment 2

[0046] Example 2: The effect of shikonin combined with fluconazole on different clinical and laboratory induced drug-resistant strains

[0047] Materials and methods

[0048] 1. Test drug:

[0049] The sources of shikonin and fluconazole are the same as above.

[0050] Dimethyl sulfoxide: China Pharmaceutical (Group) Shanghai Chemical Reagent Company.

[0051] The concentration of shikonin was 8 mg / ml, the concentration of fluconazole was 2 mg / ml, and the tested drugs were stored at -20°C. Before the experiment, the drug stock solution was taken out and placed in a 35°C incubator to melt, fully mixed, and the pharmacodynamic test was carried out respectively.

[0052] 2. Strains:

[0053] Clinical drug-resistant strain: Candida albicans, provided by the Fungi Department of Shanghai Changhai Hospital, confirmed by morphological and biochemical identification.

[0054] Drug-resistant strains induced in the laboratory: Candida albicans (SC5314-R, Y01-R) are drug-resistant stra...

Embodiment 3

[0062] Embodiment 3: Combination of shikonin and miconazole, ketoconazole

[0063] Materials and methods

[0064] 1. Test drug:

[0065] Shikonin: National Institute for the Control of Pharmaceutical and Biological Products.

[0066] Fluconazole: Pfizer Pharmaceuticals Ltd.

[0067] Ketoconazole: National Institute for the Control of Pharmaceutical and Biological Products.

[0068] Miconazole: National Institute for the Control of Pharmaceutical and Biological Products.

[0069] Dimethyl sulfoxide: China Pharmaceutical (Group) Shanghai Chemical Reagent Company.

[0070] The concentration of shikonin was 8 mg / ml, the concentration of miconazole and ketoconazole was 6.4 mg / ml, and the tested drugs were stored at -20°C. Before the experiment, the drug stock solution was taken out and placed in a 35°C incubator to melt, fully mixed, and the pharmacodynamic test was carried out respectively.

[0071] Other experimental steps and methods are the same as in Example 1.

[0072]...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicine technology and is especially new use of shikonin as an antifungal medicine synergist. The antifungal medicine comprises azole or polyene antifungal medicine and the like, the charge of shikonin is 1-16 mu g / ml in the antifungal medicine. Experiments show that when shikonin is used with the antifungal medicines such as fluconazole, ketoconazole, miconazole or amphotericin B and the like, the treatment effect of superfacial or deep fungal infection can be ensured under the circumstances of reduction of dosage, and the effects of the antifungal medicines to resistant fungi are recovered, thereby that shikonin can be used as antifungal medicine synergist with the advantages of reducing dosages of azole or polyene antifungal medicine so as to reduce side effects of medicines, especially recovering the effects of the antifungal medicines to resistant fungi to treat resistant fungal infection, and having important clinical application value.

Description

technical field [0001] The invention relates to the technical field of medicine, and relates to a new application of shikonin as a synergist of antifungal drugs. Background technique [0002] Antifungal drugs such as azoles (including imidazoles and triazoles) and polyenes are commonly used clinically and can effectively treat deep and superficial fungal infections, such as ketoconazole and clotrimazol in imidazoles azole, miconazole, econazole, etc.; fluconazole, itraconazole, voriconazole, etc. in triazoles; amphotericin B in polyenes, etc. However, due to well-known reasons, clinical drug-resistant strains are becoming more and more common, resulting in the need to increase the dosage, and some antifungal drugs are ineffective even by increasing the dosage. Increasing the dosage will inevitably increase the toxic and side effects, especially drugs such as ketoconazole and other toxic side effects on the liver or heart, thereby limiting the clinical application of these d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4196A61K31/496A61K31/4174A61K31/7048A61P31/10
Inventor 朱臻宇曹颖瑛郑泽宇王慧柴逸峰姜远英娄子洋
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com